We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
-9.64%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$585M
AUM Growth
-$73.1M
Cap. Flow
+$1.63M
Cap. Flow %
0.28%
Top 10 Hldgs %
31.26%
Holding
141
New
43
Increased
25
Reduced
14
Closed
51

Top Buys

Rank Stock Value
1
GRFS
Grifois
GRFS
+$10.6M
2
XENT
Intersect ENT, Inc
XENT
+$6.54M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$5.92M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$5.92M
5
ESTA icon
Establishment Labs
ESTA
+$5.5M

Top Sells

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$10.1M
2
DHR icon
Danaher
DHR
+$7.15M
3
ARQL
Arqule Inc
ARQL
+$6.98M
4
GH icon
Guardant Health
GH
+$6.04M
5
ABBV icon
AbbVie
ABBV
+$5.82M

Sector Composition

Rank Sector Weight
1 Healthcare 39.74%
2 Industrials 1.15%
3 Consumer Staples 0.71%
4 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCM
51
CALL
DELISTED
R1 RCM Inc. Common Stock
RCM
$3.13M 0.53%
+350,000
New +$4.13M
UTHR icon
52
United Therapeutics
UTHR
$22.1B
$3.11M 0.53%
39,000
– –
WMGI
53
CALL
DELISTED
Wright Medical Group Inc
WMGI
$3.1M 0.53%
+150,000
New +$3.57M
IVC
54
CALL
DELISTED
Invacare Corporation
IVC
$3M 0.51%
+400,000
New +$2.24M
MASI
55
DELISTED
Masimo
MASI
$2.99M 0.51%
20,099
-17,401
-46% -$2.64M
APYX icon
56
Apyx Medical
APYX
$127M
$2.88M 0.49%
425,872
+28,600
+7% +$203K
SUPN icon
57
PUT
Supernus Pharmaceuticals
SUPN
$2.73B
$2.75M 0.47%
+100,000
New +$2.96M
BYND icon
58
PUT
Beyond Meat
BYND
$215M
$2.6M 0.44%
+17,500
New +$2.88M
CSTL icon
59
Castle Biosciences
CSTL
$985M
$2.38M 0.41%
+131,718
New +$2.92M
OTIC
60
DELISTED
Otonomy, Inc.
OTIC
$2.37M 0.41%
993,463
– –
TNDM icon
61
Tandem Diabetes Care
TNDM
$1.63B
$2.36M 0.4%
40,000
+30,000
+300% +$1.91M
LAB icon
62
Standard BioTools
LAB
$309M
$2.31M 0.4%
500,000
+260,000
+108% +$2.05M
BDSI
63
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$2.17M 0.37%
515,111
-110,124
-18% -$470K
CYTK icon
64
Cytokinetics
CYTK
$10.6B
$2.14M 0.37%
+188,096
New +$2.36M
VRAY
65
DELISTED
ViewRay, Inc.
VRAY
$2.13M 0.36%
734,994
-115,006
-14% -$681K
ACHN
66
DELISTED
Achillion Pharmaceuticals
ACHN
$2.04M 0.35%
+566,600
New +$2.18M
TGTX icon
67
TG Therapeutics
TGTX
$7.64B
$1.99M 0.34%
354,719
– –
MSON
68
DELISTED
Misonix Inc
MSON
$1.88M 0.32%
93,645
+600
+0.6% +$13K
CMD
69
PUT
DELISTED
Cantel Medical Corporation
CMD
$1.87M 0.32%
+25,000
New +$2.12M
BHVN
70
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$1.67M 0.29%
+40,000
New +$1.69M
NVAX icon
71
CALL
Novavax
NVAX
$1.31B
$1.65M 0.28%
327,800
– –
CBAY
72
CALL
DELISTED
Cymabay Therapeutics
CBAY
$1.54M 0.26%
+300,000
New +$1.82M
SAGE
73
CALL
DELISTED
Sage Therapeutics
SAGE
$1.4M 0.24%
+10,000
New +$1.67M
DCPH
74
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$1.39M 0.24%
+41,000
New +$1.21M
LAB icon
75
CALL
Standard BioTools
LAB
$309M
$1.39M 0.24%
+300,000
New +$2.36M
1 2
3
4 5

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q3 2019 Portfolio in Review

As of Q3 2019, Pura Vida Investments held 141 positions worth $585M, down 11% from $658M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Pura Vida Investments's Q3 2019 filing shows 43 new, 25 increased, 14 reduced and 51 closed positions. Its largest new stake was Grifois: 496,201 shares worth $9.94M. The largest sale was Boston Scientific, an estimated $10.1M.

By sector, the portfolio is most concentrated in Healthcare at 40% of assets, down from 45% a quarter earlier, followed by Industrials and Consumer Staples.

  • Pura Vida Investments's largest Q3 2019 buy was Grifois: 496,201 shares worth $9.94M.
  • Pura Vida Investments added most to Intersect ENT, Inc in Q3 2019, an estimated $6.54M increase.
  • Pura Vida Investments's biggest Q3 2019 reduction was Zimmer Biomet, cutting an estimated $5.66M.
  • Pura Vida Investments fully exited Boston Scientific in Q3 2019, selling an estimated $10.1M.
  • Pura Vida Investments's ten largest holdings make up 31% of its $585M portfolio in Q3 2019.
  • Pura Vida Investments opened 43 new positions and closed 51 in Q3 2019.
  • Pura Vida Investments's portfolio value fell 11% quarter-over-quarter to $585M.

Based on Pura Vida Investments's 13F filing for Q3 2019, filed 14 Nov 2019.